Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐ mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies
American Journal of Hematology · 2024-10 · 99 (10) · 1862-1869
DOI: 10.1002/ajh.27416 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 12.06.2024. Verfasst von Naseema Gangat und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Aspirin, Thrombocythemia, Essential, Janus Kinase 2, Calreticulin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Two‐hundred pregnancies involving 100 women with essential thrombocythemia (ET) were accessed from Mayo Clinic databases (1990–2023). Median platelet count displayed a decline during pregnancy, nadiring at 48% of baseline, in the third trimester: 704–369 × 10 9 /L. Live birth rate was 72%. Of 53 (27%) unintentional pregnancy losses, 48 (24%) occurred in the first trimester. Other fetal complications included preterm birth 3%, intrauterine growth retardation 3%, and stillbirth 1%. Maternal complications included major hemorrhage (7%), preeclampsia (6%), thrombosis (1%), and placental abruption (0.5%). Antepartum management included no specific therapy in 52 (26%), aspirin alone in 112 (56%), aspirin combined with cytoreductive drugs or systemic anticoagulants in 23 (12%), and other permutations in the remaining. Postpartum systemic anticoagulation was documented in 29 (15%) pregnancies. Unintentional first‐trimester loss was predicted by prior fetal loss (43% vs. 18%; p < .01), diabetes mellitus (DM; 67% vs. 23%; p = .02), and absence of aspirin therapy (45% vs. 14%; p < .01); the salutary effect of aspirin therapy was independent of the other two risk factors and apparent in both high (presence of ≥1 risk factor; 33% vs. 61%; p = .07) and low (absence of both risk factors; 10% vs. 34%; p < .01) risk scenarios. The benefit of aspirin therapy, in preventing first‐trimester loss, was significant in both JAK2 ‐mutated (18% vs. 50%; p < .01) and CALR ‐mutated (8% vs. 43%; p < .01) cases. Aspirin use was also associated with a lower risk of venous thrombosis (0% vs. 3%; p = .03). By contrast, the use of systemic anticoagulation, antepartum or postpartum, did not influence fetal or maternal complication rates. CALR mutation and DM predicted maternal hemorrhage (13% vs. 4%; p = .05) and preeclampsia (33% vs. 5%; p = .03), respectively. The current study demonstrates the protective role of aspirin in preventing first‐trimester loss in ET, independent of driver mutation status or other risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.
ORCID-Profile: Naseema Gangat, Amritpal Singh, Giuseppe Gaetano Loscocco, Michelle Elliott, Kebede Begna, Animesh Pardanani, Ayalew Tefferi
Zitieren
APA
Gangat, N., Singh, A., Ilyas, R., Loscocco, G. G., Elliott, M., Begna, K., Pardanani, A., & Tefferi, A. (2024). Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐ mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies. American Journal of Hematology, 99(10), 1862-1869. https://doi.org/10.1002/ajh.27416
Vancouver
Gangat N, Singh A, Ilyas R, Loscocco GG, Elliott M, Begna K, et al. Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐ mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies. American Journal of Hematology. 2024;99(10):1862-1869. doi:10.1002/ajh.27416
BibTeX
@article{Gangat2024,
author = {Gangat, Naseema and Singh, Amritpal and Ilyas, Rimal and Loscocco, Giuseppe Gaetano and Elliott, Michelle and Begna, Kebede and Pardanani, Animesh and Tefferi, Ayalew},
title = {Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐ mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {10},
pages = {1862--1869},
doi = {10.1002/ajh.27416}
}
EUVIMED